Garry S. Ceccon

Kerpener St. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma.

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma.

Journal: Neuro-oncology advances

Published: September 26, 2025

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria.

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria.

Journal: Neuro-oncology advances

Published: June 25, 2025

Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.

Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 20, 2025

The Value of Multidisciplinary Neuro-oncological Tumor Boards to Increase the Accuracy of FET PET for Identifying Brain Tumor Relapse.

The Value of Multidisciplinary Neuro-oncological Tumor Boards to Increase the Accuracy of FET PET for Identifying Brain Tumor Relapse.

Journal: Clinical nuclear medicine

Published: January 14, 2025

Borderline Findings in O-(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.

Borderline Findings in O-(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 09, 2024

PET imaging of gliomas: Status quo and quo vadis?

PET imaging of gliomas: Status quo and quo vadis?

Journal: Neuro-oncology

Published: July 06, 2024

MRI and 18F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis.

MRI and 18F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 23, 2023

Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET.

Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 14, 2023

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.

Journal: Journal of neuro-oncology

Published: November 15, 2022

Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.

Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.

Journal: Neuro-oncology

Published: October 10, 2022

Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience.

Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience.

Journal: Cancers

Published: May 31, 2022

Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.

Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.

Journal: Journal of neuro-oncology

Published: May 12, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026